Literature DB >> 32791233

The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma.

Raul Caso1, Francisco Sanchez-Vega2, Kay See Tan3, Brooke Mastrogiacomo4, Jian Zhou1, Gregory D Jones1, Bastien Nguyen5, Nikolaus Schultz5, James G Connolly1, Whitney S Brandt1, Matthew J Bott6, Gaetano Rocco6, Daniela Molena6, James M Isbell6, Yuan Liu6, Marty W Mayo7, Prasad S Adusumilli6, William D Travis8, David R Jones9.   

Abstract

INTRODUCTION: The purpose of the study is to genomically characterize the biology and related therapeutic opportunities of prognostically important predominant histologic subtypes in lung adenocarcinoma (LUAD).
METHODS: We identified 604 patients with stage I to III LUAD who underwent complete resection and targeted next-generation sequencing using the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets platform. Tumors were classified according to predominant histologic subtype and grouped by architectural grade (lepidic [LEP], acinar or papillary [ACI/PAP], and micropapillary or solid [MIP/SOL]). Associations among clinicopathologic factors, genomic features, mutational signatures, and recurrence were evaluated within subtypes and, when appropriate, quantified using competing-risks regression, with adjustment for pathologic stage and extent of resection.
RESULTS: MIP/SOL tumors had higher tumor mutational burden (p < 0.001), fraction of genome altered (p = 0.001), copy number amplifications (p = 0.021), rate of whole-genome doubling (p = 0.008), and number of oncogenic pathways altered ( p < 0.001) as compared with LEP and ACI/PAP tumors. Across all tumors, mutational signatures attributed to APOBEC activity were associated with the highest risk of postresection recurrence: SBS2 (p = 0.021) and SBS13 (p = 0.005). Three oncogenic pathways (p53, Wnt, Myc) were altered with statistical significance in MIP/SOL tumors. Compared with LEP and ACI/PAP tumors, MIP/SOL tumors had a higher frequency of targetable BRAF-V600E mutations (p = 0.046). Among ACI/PAP tumors, alterations in the cell cycle (p < 0.001) and PI3K (p = 0.002) pathways were associated with recurrence; among MIP/SOL tumors, only PI3K alterations were associated with recurrence (p = 0.049).
CONCLUSIONS: These results provide the first in-depth assessment of tumor genomic profiling of predominant LUAD histologic subtypes, their associations with recurrence, and their correlation with targetable driver alterations in patients with surgically resected LUAD.
Copyright © 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Histologic subtypes; Lung adenocarcinoma; Next-generation sequencing; Tumor genomic profiling

Mesh:

Year:  2020        PMID: 32791233      PMCID: PMC7704768          DOI: 10.1016/j.jtho.2020.08.005

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  52 in total

1.  FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing.

Authors:  Ronglai Shen; Venkatraman E Seshan
Journal:  Nucleic Acids Res       Date:  2016-06-07       Impact factor: 16.971

2.  New approaches to molecular diagnosis.

Authors:  Bruce R Korf; Heidi L Rehm
Journal:  JAMA       Date:  2013-04-10       Impact factor: 56.272

3.  Multiple primary lung cancers.

Authors:  N Martini; M R Melamed
Journal:  J Thorac Cardiovasc Surg       Date:  1975-10       Impact factor: 5.209

4.  Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases.

Authors:  Akihiko Yoshizawa; Noriko Motoi; Gregory J Riely; Cami S Sima; William L Gerald; Mark G Kris; Bernard J Park; Valerie W Rusch; William D Travis
Journal:  Mod Pathol       Date:  2011-01-21       Impact factor: 7.842

5.  Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

Authors:  Whijae Roh; Pei-Ling Chen; Alexandre Reuben; Christine N Spencer; Peter A Prieto; John P Miller; Vancheswaran Gopalakrishnan; Feng Wang; Zachary A Cooper; Sangeetha M Reddy; Curtis Gumbs; Latasha Little; Qing Chang; Wei-Shen Chen; Khalida Wani; Mariana Petaccia De Macedo; Eveline Chen; Jacob L Austin-Breneman; Hong Jiang; Jason Roszik; Michael T Tetzlaff; Michael A Davies; Jeffrey E Gershenwald; Hussein Tawbi; Alexander J Lazar; Patrick Hwu; Wen-Jen Hwu; Adi Diab; Isabella C Glitza; Sapna P Patel; Scott E Woodman; Rodabe N Amaria; Victor G Prieto; Jianhua Hu; Padmanee Sharma; James P Allison; Lynda Chin; Jianhua Zhang; Jennifer A Wargo; P Andrew Futreal
Journal:  Sci Transl Med       Date:  2017-03-01       Impact factor: 17.956

6.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

7.  Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.

Authors:  Jianjun Zhang; Junya Fujimoto; Jianhua Zhang; David C Wedge; Xingzhi Song; Jiexin Zhang; Sahil Seth; Chi-Wan Chow; Yu Cao; Curtis Gumbs; Kathryn A Gold; Neda Kalhor; Latasha Little; Harshad Mahadeshwar; Cesar Moran; Alexei Protopopov; Huandong Sun; Jiabin Tang; Xifeng Wu; Yuanqing Ye; William N William; J Jack Lee; John V Heymach; Waun Ki Hong; Stephen Swisher; Ignacio I Wistuba; P Andrew Futreal
Journal:  Science       Date:  2014-10-10       Impact factor: 47.728

8.  Tracking the Evolution of Non-Small-Cell Lung Cancer.

Authors:  Mariam Jamal-Hanjani; Gareth A Wilson; Nicholas McGranahan; Nicolai J Birkbak; Thomas B K Watkins; Selvaraju Veeriah; Seema Shafi; Diana H Johnson; Richard Mitter; Rachel Rosenthal; Max Salm; Stuart Horswell; Mickael Escudero; Nik Matthews; Andrew Rowan; Tim Chambers; David A Moore; Samra Turajlic; Hang Xu; Siow-Ming Lee; Martin D Forster; Tanya Ahmad; Crispin T Hiley; Christopher Abbosh; Mary Falzon; Elaine Borg; Teresa Marafioti; David Lawrence; Martin Hayward; Shyam Kolvekar; Nikolaos Panagiotopoulos; Sam M Janes; Ricky Thakrar; Asia Ahmed; Fiona Blackhall; Yvonne Summers; Rajesh Shah; Leena Joseph; Anne M Quinn; Phil A Crosbie; Babu Naidu; Gary Middleton; Gerald Langman; Simon Trotter; Marianne Nicolson; Hardy Remmen; Keith Kerr; Mahendran Chetty; Lesley Gomersall; Dean A Fennell; Apostolos Nakas; Sridhar Rathinam; Girija Anand; Sajid Khan; Peter Russell; Veni Ezhil; Babikir Ismail; Melanie Irvin-Sellers; Vineet Prakash; Jason F Lester; Malgorzata Kornaszewska; Richard Attanoos; Haydn Adams; Helen Davies; Stefan Dentro; Philippe Taniere; Brendan O'Sullivan; Helen L Lowe; John A Hartley; Natasha Iles; Harriet Bell; Yenting Ngai; Jacqui A Shaw; Javier Herrero; Zoltan Szallasi; Roland F Schwarz; Aengus Stewart; Sergio A Quezada; John Le Quesne; Peter Van Loo; Caroline Dive; Allan Hackshaw; Charles Swanton
Journal:  N Engl J Med       Date:  2017-04-26       Impact factor: 91.245

9.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers.

Authors:  Craig H Mermel; Steven E Schumacher; Barbara Hill; Matthew L Meyerson; Rameen Beroukhim; Gad Getz
Journal:  Genome Biol       Date:  2011-04-28       Impact factor: 13.583

Review 10.  Using single-cell multiple omics approaches to resolve tumor heterogeneity.

Authors:  Michael A Ortega; Olivier Poirion; Xun Zhu; Sijia Huang; Thomas K Wolfgruber; Robert Sebra; Lana X Garmire
Journal:  Clin Transl Med       Date:  2017-12-28
View more
  16 in total

1.  CT-based Radiogenomic Analysis of Clinical Stage I Lung Adenocarcinoma with Histopathologic Features and Oncologic Outcomes.

Authors:  Rocio Perez-Johnston; Jose A Araujo-Filho; James G Connolly; Raul Caso; Karissa Whiting; Kay See Tan; Jian Zhou; Peter Gibbs; Natasha Rekhtman; Michelle S Ginsberg; David R Jones
Journal:  Radiology       Date:  2022-03-01       Impact factor: 29.146

2.  Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.

Authors:  Bastien Nguyen; Christopher Fong; Anisha Luthra; Shaleigh A Smith; Renzo G DiNatale; Subhiksha Nandakumar; Henry Walch; Walid K Chatila; Ramyasree Madupuri; Ritika Kundra; Craig M Bielski; Brooke Mastrogiacomo; Mark T A Donoghue; Adrienne Boire; Sarat Chandarlapaty; Karuna Ganesh; James J Harding; Christine A Iacobuzio-Donahue; Pedram Razavi; Ed Reznik; Charles M Rudin; Dmitriy Zamarin; Wassim Abida; Ghassan K Abou-Alfa; Carol Aghajanian; Andrea Cercek; Ping Chi; Darren Feldman; Alan L Ho; Gopakumar Iyer; Yelena Y Janjigian; Michael Morris; Robert J Motzer; Eileen M O'Reilly; Michael A Postow; Nitya P Raj; Gregory J Riely; Mark E Robson; Jonathan E Rosenberg; Anton Safonov; Alexander N Shoushtari; William Tap; Min Yuen Teo; Anna M Varghese; Martin Voss; Rona Yaeger; Marjorie G Zauderer; Nadeem Abu-Rustum; Julio Garcia-Aguilar; Bernard Bochner; Abraham Hakimi; William R Jarnagin; David R Jones; Daniela Molena; Luc Morris; Eric Rios-Doria; Paul Russo; Samuel Singer; Vivian E Strong; Debyani Chakravarty; Lora H Ellenson; Anuradha Gopalan; Jorge S Reis-Filho; Britta Weigelt; Marc Ladanyi; Mithat Gonen; Sohrab P Shah; Joan Massague; Jianjiong Gao; Ahmet Zehir; Michael F Berger; David B Solit; Samuel F Bakhoum; Francisco Sanchez-Vega; Nikolaus Schultz
Journal:  Cell       Date:  2022-02-03       Impact factor: 66.850

3.  Tumor Histological Grade and Immunotherapy Response in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Authors:  Hosam H Alkhatib; Christopher A Maroun; Neha Amin; Gangcai Zhu; Meytal Guller; Matthew E Herberg; Evan S Wu; Tanguy Y Seiwert; Lisa M Rooper; David W Eisele; Carole Fakhry; Drew Pardoll; Rajarsi Mandal
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2022-06-01       Impact factor: 8.961

4.  The prognostic utility of the histologic subtype of stage I lung adenocarcinoma may be diminished when using only the invasive component to determine tumor size for tumor node metastasis (TNM) staging.

Authors:  Yeoun Eun Sung; Kyo Young Lee; Youngkyu Moon
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 2.895

5.  KRAS G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma.

Authors:  Gregory D Jones; Raul Caso; Kay See Tan; Brooke Mastrogiacomo; Francisco Sanchez-Vega; Yuan Liu; James G Connolly; Yonina R Murciano-Goroff; Matthew J Bott; Prasad S Adusumilli; Daniela Molena; Gaetano Rocco; Valerie W Rusch; Smita Sihag; Sandra Misale; Rona Yaeger; Alexander Drilon; Kathryn C Arbour; Gregory J Riely; Neal Rosen; Piro Lito; Haiying Zhang; David C Lyden; Charles M Rudin; David R Jones; Bob T Li; James M Isbell
Journal:  Clin Cancer Res       Date:  2021-02-16       Impact factor: 13.801

6.  Transcriptional patterns reveal tumor histologic heterogeneity and immunotherapy response in lung adenocarcinoma.

Authors:  Mengxue Jiao; Hui Liu; Xuejun Liu
Journal:  Front Immunol       Date:  2022-08-08       Impact factor: 8.786

7.  Preoperative clinical and tumor genomic features associated with pathologic lymph node metastasis in clinical stage I and II lung adenocarcinoma.

Authors:  Raul Caso; James G Connolly; Jian Zhou; Kay See Tan; James J Choi; Gregory D Jones; Brooke Mastrogiacomo; Francisco Sanchez-Vega; Bastien Nguyen; Gaetano Rocco; Daniela Molena; Smita Sihag; Prasad S Adusumilli; Matthew J Bott; David R Jones
Journal:  NPJ Precis Oncol       Date:  2021-07-21

Review 8.  The Emerging Importance of Tumor Genomics in Operable Non-Small Cell Lung Cancer.

Authors:  Harry B Lengel; James G Connolly; Gregory D Jones; Raul Caso; Jian Zhou; Francisco Sanchez-Vega; Brooke Mastrogiacomo; James M Isbell; Bob T Li; Yuan Liu; Natasha Rekhtman; David R Jones
Journal:  Cancers (Basel)       Date:  2021-07-21       Impact factor: 6.575

9.  Intraoperative opioid exposure, tumour genomic alterations, and survival differences in people with lung adenocarcinoma.

Authors:  James G Connolly; Kay See Tan; Brooke Mastrogiacomo; Joseph Dycoco; Raul Caso; Gregory D Jones; Patrick J McCormick; Francisco Sanchez-Vega; Takeshi Irie; Joseph R Scarpa; Hersh V Gupta; Prasad S Adusumilli; Gaetano Rocco; James M Isbell; Matthew J Bott; Gregory W Fischer; David R Jones; Joshua S Mincer
Journal:  Br J Anaesth       Date:  2021-07       Impact factor: 11.719

10.  LncRNA SNHG20 promoted proliferation, invasion and inhibited cell apoptosis of lung adenocarcinoma via sponging miR-342 and upregulating DDX49.

Authors:  Xiuli Wang; Guomin Gu; Hongge Zhu; Suqiong Lu; Kahaerjiang Abuduwaili; Chunling Liu
Journal:  Thorac Cancer       Date:  2020-10-22       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.